Welcome to our dedicated page for Bruker Corporation news (Ticker: BRKR), a resource for investors and traders seeking the latest updates and insights on Bruker Corporation stock.
Bruker Corporation (symbol: BRKR) stands as a global leader in analytical instrumentation. With over fifty years of innovation, Bruker aims to provide top-tier technological solutions for various analytical tasks. Headquartered in Massachusetts, USA, Bruker employs more than 6,500 individuals across 90 locations worldwide.
The company's operations are categorized into four main segments:
- BSI BioSpin: Specializes in magnetic resonance technologies, including NMR, EPR, and preclinical MRI systems.
- BSI CALID: Focuses on mass spectrometry, chromatography, molecular spectroscopy, and in vitro diagnostics.
- BSI Nano: Offers solutions in X-ray diffraction, elemental analysis, atomic force microscopy, and surface and dimensional metrology.
- Bruker Energy & Supercon Technologies (BEST): Provides superconducting materials and devices for energy, science, and healthcare sectors.
Bruker demonstrates a strong commitment to research and development, continuously expanding its suite of products and maintaining a robust installed base globally. The company’s dedication to quality and reliability is reflected in its significant presence in the Asia Pacific region, which accounts for the largest share of its revenue.
Recent achievements include advancements in mass spectrometry and collaborations with leading pharmaceutical and biotechnology companies. Bruker's technologies are vital for quality assurance in industrial production processes, supporting customers in ensuring precision and reliability.
Bruker Corporation is not just a manufacturer but a partner in innovation, helping scientists and researchers address complex analytical challenges with integrity and cutting-edge technology.
Bruker Corporation (NASDAQ: BRKR) showcased its innovative scientific instruments and solutions at Analytica 2022, emphasizing advancements in materials and energy research, as well as biopharmaceuticals. Notable product launches include the HYPERION II FT-IR microscope, TGA II FT-IR module, and DART-EVOQ mass spectrometry system, enhancing analytical capabilities across industries. The introduction of Spatial Single-Cell Metabolomics signifies a leap in cancer research and cell biology. These innovations aim to improve laboratory efficiency and analytical precision for a range of applications.
Bruker Corporation (Nasdaq: BRKR) has launched the NeuraLight 3D Ultra module, enhancing its Ultima multiphoton microscopes for advanced neuroscience and optogenetics research. This module features 3D holographic photostimulation, a larger liquid crystal chip for improved targeting, and a speed of 600 hologram frames per second. It allows researchers to study neural networks more effectively. The NeuraLight 3D Ultra is compatible with newer and selected older Ultima models, promoting innovation in neuroscience research.
Bruker Corporation (Nasdaq: BRKR) showcased innovations at the 70th ASMS Conference, unveiling advancements in spatial multiomics for tissue and tumor microenvironments. The MALDI HiPLEX-IHC technology integrates protein expression profiling with small molecule imaging, enhancing high-plex protein mapping and metabolic process elucidation.
The new microGRID module for the timsTOF fleX platform and SCiLS Lab 2023a software improvements facilitate virtually artifact-free imaging and advanced analytics, positioning Bruker at the forefront of cancer research innovation.
Bruker Corporation has unveiled the timsTOF HT system at the 70th ASMS meeting, enhancing its 4D Multiomics platform with a fourth-generation TIMS XR cell and a 14-bit digitizer. This innovation boosts dynamic range and peptide coverage, enabling the identification of over 100,000 unique peptides with high quantification accuracy. The system supports high-throughput proteomics, achieving sample processing rates of up to 200 samples per day. Additionally, the PaSER mode allows real-time data streaming for intelligent acquisition, further advancing metabolomics and biomarker discovery.
Bruker Corporation (NASDAQ: BRKR) has expanded its mass spectrometry capabilities by acquiring IonSense, the developer of DART™ technology, enhancing Point-of-Need (PoN) analysis. The newly launched DART-EVOQ® triple quadrupole mass spectrometer allows quick analyses across various sectors like food, forensics, and pharmaceuticals without the need for chromatography. Additionally, Bruker has partnered with TOFWERK AG to accelerate the development of high-speed analytical solutions. These strategic moves aim to position Bruker as a leader in PoN mass spectrometry.
Bruker Corporation (Nasdaq: BRKR) will present at the Jefferies 2022 Global Healthcare Conference in New York on June 9, 2022, at 3:00 pm EDT. Frank Laukien, CEO, and Justin Ward, Sr. Director of Investor Relations, will represent the company. A live audio webcast will be available on the Investor Relations section of Bruker's website, with a replay accessible for 30 days post-event. Bruker is dedicated to advancing scientific discovery and enhancing human life through its innovative analytical solutions and high-performance scientific instruments.
Bruker Corporation (NASDAQ: BRKR) announced the approval of a quarterly cash dividend of
Bruker is dedicated to advancing scientific discovery through high-performance instruments and analytical solutions that enhance human life quality. The company operates in various domains including life sciences, applied markets, and industrial applications.
Bruker Corporation (BRKR) has entered a strategic partnership with TOFWERK AG, including a minority investment by Bruker in TOFWERK. This collaboration focuses on enhancing high-speed and ultra-sensitive analytical solutions, particularly in mass spectrometry for small molecules and volatile compounds. The partnership aims to leverage Bruker’s commercial scale to boost TOFWERK’s market presence. Innovations include advanced instrument capabilities and applications for ambient air analysis, breath diagnostics, and semiconductor monitoring.
Bruker Corporation reported Q1 2022 revenues of $595.0 million, a 7.3% year-over-year increase. Organic revenue growth was notable at 10.5%. The company saw GAAP diluted EPS rise to $0.41, up from $0.37 in Q1 2021. With strong demand for its life science tools, Bruker raised its FY 2022 organic revenue outlook to 7% to 9% and expects non-GAAP EPS between $2.29 to $2.33, reflecting a 9% to 11% increase year-over-year. The firm also made key acquisitions to bolster growth.
FAQ
What is the current stock price of Bruker Corporation (BRKR)?
What is the market cap of Bruker Corporation (BRKR)?
What does Bruker Corporation specialize in?
How is Bruker Corporation structured?
Where does Bruker generate most of its revenue?
How many employees does Bruker Corporation have?
What industries does Bruker serve?
What recent advancements has Bruker made?
What is BSI BioSpin known for?
Why are Bruker's technologies important in industrial production?
What is the BEST segment of Bruker Corporation?
How does Bruker Corporation contribute to scientific research?
